Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Base rate

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    303 result(s) found for: Base rate. Displaying page 4 of 16.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-001569-97 Sponsor Protocol Number: AGO/2016/004 Start Date*: 2017-06-19
    Sponsor Name:University Hospital Ghent
    Full Title: A phase II Investigation of Pembrolizumab (Keytruda) in combination with radiation and an immune modulatory cocktail in patients with cervical and uterine cancer.
    Medical condition: cervical cancer, endometrial carcinoma, uterine sarcoma
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-003593-16 Sponsor Protocol Number: D4200C00055 Start Date*: 2005-11-23
    Sponsor Name:AstraZeneca AB
    Full Title: A phase II, double-blind, placebo-controleed, randomised study to assess the efficacy and safety of docetaxel (Taxotere)/ prednisolone/ ZD6474 vs. docetaxel/ prednisolone/ placebo in patients with ...
    Medical condition: Hormone refractory prostate cancer (HRPC)
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000392-14 Sponsor Protocol Number: 1200.131 Start Date*: 2011-07-27
    Sponsor Name:Boehringer Ingelheim Limited
    Full Title: LUX-Head & Neck 2 A randomised, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemoradiotherapy in primary...
    Medical condition: Loco-regionally advanced head and neck squamous cell carcinoma with no evidence of disease after chemo-radiotherapy
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Prematurely Ended) BE (Completed) FR (Prematurely Ended) NL (Prematurely Ended) DE (Completed) FI (Prematurely Ended) GR (Prematurely Ended) AT (Prematurely Ended) SE (Prematurely Ended) IT (Completed) CZ (Prematurely Ended) DK (Prematurely Ended) PT (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003024-16 Sponsor Protocol Number: ACT16482 Start Date*: 2021-06-30
    Sponsor Name:Sanofi-Aventis Recherche & Developpement
    Full Title: Phase 1-2 UMBRELLA trial evaluating isatuximab with or without dexamethasone in combination with novel agents in relapsed or refractory multiple myeloma (RRMM) - Master protocol
    Medical condition: Plasma cell myeloma refractory
    Disease: Version SOC Term Classification Code Term Level
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10081847 Plasma cell myeloma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) FR (Completed) GR (Trial now transitioned) PT (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-000448-26 Sponsor Protocol Number: ITOFD04-03 Start Date*: 2005-01-05
    Sponsor Name:Axcan Pharma Inc. (Axcan Pharma International BV is subsidiary of Axcan Pharma Inc.)
    Full Title: A multicentre, randomized, double-blind, placebo-controlled study of the efficacy and safety of Itopride HCl in patients suffering from functional dyspepsia
    Medical condition: Treatment of abdominal symptoms in patients with functional dyspepsia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-008720-33 Sponsor Protocol Number: PDP007 Start Date*: 2009-06-08
    Sponsor Name:Cliniques Universitaires St Luc
    Full Title: A one year, open, prospective study on the role of quarterly intravitreal injections of Lucentis 0,5 mg (ranibizumab) in preventing of delaying progression of radiation retinopathy in eyes treated ...
    Medical condition: Radiation retinopathy in eyes treated with Iodine 125 plaque radiotherapy for posterior uveal melanoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064714 Radiation retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014344-11 Sponsor Protocol Number: prot-001-2009 Start Date*: 2010-06-02
    Sponsor Name:Imperial College London
    Full Title: Neuroprotective effects of hypothermia combined with inhaled xenon following perinatal asphyxia - the TOBY Xe trial
    Medical condition: Neonatal asphyxial encephalopathy
    Disease: Version SOC Term Classification Code Term Level
    12 10028946 neonatal hypoxia and asphyxia SOC
    Population Age: Newborns, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-011250-17 Sponsor Protocol Number: CNTO888OVC2001 Start Date*: 2010-03-01
    Sponsor Name:Centocor B.V.
    Full Title: Estudio abierto, multicéntrico, Fase 2 de CNTO 888 (anticuerpo monoclonal anti-CCL2) como agente único para el tratamiento de sujetos con cáncer de ovario recurrente.
    Medical condition: Cáncer de ovario recurrente
    Disease: Version SOC Term Classification Code Term Level
    12.0 10066697 Ovarian cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-013402-14 Sponsor Protocol Number: INTECEPTOR-TRIAL Start Date*: 2009-09-17
    Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST
    Full Title: INduction chemoThERapy followed by CEtuximab Plus definiTive radiOtheRapy versus radiation plus cisplatin
    Medical condition: locally advanced squamous cell carcinoma of the head and neck
    Disease: Version SOC Term Classification Code Term Level
    12.0 10063569 Metastatic squamous cell carcinoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005040-85 Sponsor Protocol Number: HaHes Start Date*: 2006-03-17
    Sponsor Name:Department of Anesthesia, Div. of Cardiothoracic and Vascular Anesthesia, Medical University Vienna
    Full Title: Comparison of Albumin 5%, Hydroxyethyl Starch 130/0.4 (6%) and Ringer Lactate for volume replacement during cardiac surgery
    Medical condition: Intensive care patients after cardiac surgery requiring volume therapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-006658-24 Sponsor Protocol Number: 8024 Start Date*: 2009-03-05
    Sponsor Name:University of Nottingham
    Full Title: A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid
    Medical condition: BP is a serious condition with a significant associated morbidity and mortality rate. Widespread tense and haemorrhagic blisters, skin erosions and severe itching cause patients a great deal of dis...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10040785 - Skin and subcutaneous tissue disorders 10006568 Bullous pemphigoid NOS LLT
    14.0 10040785 - Skin and subcutaneous tissue disorders 10006567 Bullous pemphigoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-000815-24 Sponsor Protocol Number: 01-2006 Start Date*: 2006-07-28
    Sponsor Name:Charité
    Full Title: A randomized study of topical 3% Diclofenac in a 2.5% Hyaluronate base (Solaraze® 3% Gel) versus topical 5% 5-Fluorouracil (Efudix® Cream) versus liquid nitrogen spray cryotherapy in immunosufficie...
    Medical condition: Actinic keratosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-004880-36 Sponsor Protocol Number: CRB Start Date*: 2013-06-17
    Sponsor Name:Medizinische Universität Graz, Klinische Abteilung für Geburtshilfe, Univ. Klinik für Frauenheilkunde und Geburtshilfe
    Full Title: Efficacy of induction of labor on term using a double balloon catheter compared to Dinoprostone vaginal-insert – a multicenter randomized controlled trial.
    Medical condition: Gestational age between the 37th and 42th gestation week
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001068-23 Sponsor Protocol Number: ACO CT 2010-01 Start Date*: 2011-07-26
    Sponsor Name:ACO Hud Nordic AB
    Full Title: Comparison of Moisturisers for the Prevention of Atopic Dermatitis Relapse– a Randomised, Double Blind Controlled Study (COMPADRE)
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10040785 - Skin and subcutaneous tissue disorders 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000414-41 Sponsor Protocol Number: PROICM2021-01GRE Start Date*: 2021-07-19
    Sponsor Name:Institut régional du Cancer de Montpellier
    Full Title: Multicentric Phase II-III study evaluating the tailored management of locally-advanced rectal carcinoma after a favorable response to Induction chemotherapy
    Medical condition: Locally advanced rectal carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10007450 Carcinoma of rectum stage III LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004031-37 Sponsor Protocol Number: 17.14 Start Date*: 2017-12-07
    Sponsor Name:Department of oncology, Odense University Hospital
    Full Title: A multicentre, single-arm, phase II study to investigate the safety and antiemetic efficacy of Akynzeo® (a fixed dose combination of palonosetron and netupitant) plus dexamethasone in patients rece...
    Medical condition: Eligible patients will have a diagnosis of cervical cancer, and be scheduled to receive fractionated radiotherapy and concomitant weekly cisplatin at a dose of ≥ 40 mg/m2 for at least five weeks. P...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000907-29 Sponsor Protocol Number: SHDE-1 Start Date*: 2014-08-25
    Sponsor Name:Hevert-Arzneimittel GmbH & Co. KG
    Full Title: Efficacy and safety of Sinusitis Hevert SL tablets compared to placebo in adult patients with acute, uncomplicated rhinosinusitis. A multicenter, randomized, double-blind, placebo-controlled, paral...
    Medical condition: acute, uncomplicated rhinosinusitis
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-000706-37 Sponsor Protocol Number: CLLG783X2201 Start Date*: 2017-11-28
    Sponsor Name:Novartis Pharma AG
    Full Title: A Patient and Investigator-blinded, randomized, placebo controlled study of LLG783 in patients with peripheral artery disease (PAD) and intermittent claudication.
    Medical condition: Peripheral Artery Disease (PAD), Intermittent Claudication
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10022562 Intermittent claudication PT
    20.0 10047065 - Vascular disorders 10034633 Peripheral vascular disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004155-39 Sponsor Protocol Number: BAY1000394/14858 Start Date*: Information not available in EudraCT
    Sponsor Name:Bayer Healthcare AG
    Full Title: Phase Ib / II study of BAY 1000394 in combination with cisplatin / etoposide or carboplatin / etoposide as first-line therapy in subjects with extensive disease small cell lung cancer
    Medical condition: Subjects with histologically or cytologically confirmed, extensive disease SCLC without prior systemic antitumor therapy are eligible. Subjects should have evaluable or measurable disease.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-005263-16 Sponsor Protocol Number: NSC15001 Start Date*: 2016-07-11
    Sponsor Name:Pharmatrophix Inc
    Full Title: A 6-months prospective, multi-center, double-blind, placebo-controlled, randomized, adaptive-trial-design study to evaluate safety, tolerability and exploratory endpoints of either placebo or two d...
    Medical condition: Mild to moderate Alzheimer's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    20.0 100000004852 10066571 Progression of Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) DE (Completed) SE (Completed) ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 16 21:53:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA